167. マルファン症候群 Marfan syndrome Clinical trials / Disease details


臨床試験数 : 20 薬物数 : 39 - (DrugBank : 10) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-001462-81-IT
(EUCTR)
27/10/200817/03/2008Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDEffects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND Marfan Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: LORTAAN*28CPR RIV DIV 50MG
INN or Proposed INN: Losartan
Trade Name: LOBIVON*28CPR 5MG
INN or Proposed INN: Nebivolol
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
Phase 3Italy
2NCT00683124
(ClinicalTrials.gov)
July 200821/5/2008Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan PatientsEffects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.Marfan SyndromeDrug: Losartan and nebivolol;Drug: Losartan;Drug: NebivololIRCCS Policlinico S. MatteoMerck Sharp & Dohme Corp.;Menarini GroupRecruiting12 Months55 YearsBoth291Phase 3Italy